Ontology highlight
ABSTRACT:
SUBMITTER: Bhatia HK
PROVIDER: S-EPMC4231565 | biostudies-other | 2014 Oct
REPOSITORIES: biostudies-other
Bhatia Harmeet Kaur HK Singh Harmanjit H Grewal Nipunjot N Natt Navreet Kaur NK
Journal of pharmacology & pharmacotherapeutics 20141001 4
Hepatitis C currently infects more than 170 million people around the world, leading to significant morbidity and mortality. The current standard of care for HCV infection, including one of the two protease inhibitors, telaprevir or boceprevir, for 12-32 weeks, along with pegylated interferon alfa-2a (PEG-IFN-α) and ribavirin for up to 48 weeks, is unsatisfactory in many cases, either because of lack of efficacy or because of treatment-related adverse effects. There is an urgent need of new drug ...[more]